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We analyzed changes in immunologic values over time 
for 28 hospitalized patients with pandemic (H1N1) 2009. 
Levels of interleukin-6, interferon-γ, and interleukin-10 
increased 1 day after illness onset and then decreased 
to baseline levels. Levels of virus-speciﬁ   c antibody were 
undetectable 1 day after illness onset and peaked 36 days 
later.
P
andemic (H1N1) 2009 virus emerged in March 2009 
and spread worldwide (1,2). Most patient laboratory 
data result from samples or information obtained on the 
day of hospitalization or when the patient was experiencing 
the acute phase of infection. Changes in laboratory data 
throughout the disease course have rarely been reported. 
We retrospectively analyzed immunologic changes 
for hospitalized patients through the entire course of 
pandemic (H1N1) 2009. These data may provide a better 
understanding of disease pathogenesis.
The Study
Twenty-eight patients admitted to Beijing 302 Hospital 
in Beijing, China, were enrolled in this study in September 
2009. All patients had mild clinical courses and fulﬁ  lled 
the case deﬁ  nition for pandemic (H1N1) 2009 (3). Median 
interval from onset of illness to hospitalization was 1 day 
(range 0–3 days), and median time of hospitalization was 
7 days (range 6–14 days). Serum samples were obtained 
from patients 1 day after illness onset and 4, 14, 36, and 48 
days later for cytokine and antibody measurement. Serum 
samples from 22 healthy persons were used to determine 
cytokine and antibody baseline levels.
Serum cytokine concentrations were detected by using 
the BD Cytometric Bead Array Human Cytokine Kit (BD 
Biosciences, San Jose, CA, USA) and a BD FACSCalibur 
ﬂ   ow cytometer, according to the manufacturer’s 
instructions. CD3 T-lymphocyte counts were <690 cells/
mm3 in 9 (32.1%) of 28 patients and represented <55% of 
total lymphocyte counts in 4 (14.3%) patients (Table). CD4 
T-lymphocyte counts were <400 cells/mm3 in 13 (46.4%) 
patients and represented <31% of total lymphocyte counts 
in 8 (28.6%) patients. CD8 T-lymphocyte counts were 
<190 cells/mm3 in 3 (10.7%) patients. B-cell counts were 
<90 cells/mm3 in 1 (3.6%) patient. Natural killer cells 
represented >27% of lymphocyte counts in 4 (14.3%) 
patients. Fourteen (50.0%) patients had a CD4:CD8 ratio 
less than the standard reference ratio of 1.4.
Flow cytometric results showing development of 
peripheral blood lymphocyte subsets during the disease 
course were divided into 3 groups on the basis of time of 
illness onset until date of blood sample collection: 1–3, 
4–6, or 7–10 days. These groups were used because the 
longest time from onset of illness to hospitalization was 3 
days for all patients, and the peak temperature for patients 
was observed 3 days after illness onset.
Mean counts and percentages of all T- and 
B-lymphocyte subsets increased after 3 days of illness 
compared with results obtained during the ﬁ  rst 3 days of 
illness (Figure 1). However, the increase in CD8 and B 
cells was not signiﬁ  cant. Another study showed a decrease 
in CD4, CD8, and B cells ≤2 days of symptom onset in 
patients with pandemic (H1N1) 2009 than in healthy 
persons (4). Our results show impaired adaptive immune 
responses and a gradual increase during recovery in mildly 
affected patients.
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Table. Flow cytometric analysis of peripheral blood lymphocyte 
subsets for 28 patients with pandemic (H1N1) 2009 at 
hospitalization, China* 
Lymphocyte subset  No. positive/no. tested (%) 
CD45 <1,500 cells/mm
3† 21/28 (75.0) 
CD3 
 <690  cells/mm
3 9/28 (32.1) 
 <55%  4/28  (14.3) 
CD4 
 <400  cells/mm
3 13/28 (46.4) 
 <31%  8/28  (28.6) 
CD8 
 <190  cells/mm
3 3/28 (10.7) 
 <13%  0/28  (0) 
B cells 
 <90  cells/mm
3 1/28 (3.6) 
 <6%  0/28  (0) 
Natural killer cells 
 >590  cells/mm
3 1/28 (3.6) 
 >27%  4/28  (14.3) 
Ratio of CD4:CD8 cells <1.4  14/28 (50.0) 
*Lymphocyte subsets were defined as the following combinations: 
CD3+/CD45+ for CD3 T-lymphocytes; CD3+/CD4/+/CD45+ for CD4 T-
lymphocytes; CD3+/CD8+/CD45+ for CD8 T-lymphocytes; CD19+/CD45+ 
for B-lymphocytes; and CD3+/CD(16+56)+/CD45+ for natural killer cells. 
†CD45 lymphocyte count was designated the total lymphocyte count. We measured serum cytokine concentrations and 
hemagglutination inhibition (HAI) antibody titers in patients 
during hospitalization and the follow-up period (Figure 
2). We observed an increase in interleulin-6 (IL-6) levels 
1 day after illness onset, which were 6.0-fold higher than 
the baseline level, and a 2.3-fold increase in interferon-γ 
(IFN-γ) levels. These levels decreased to baseline levels 
5 days after illness onset, although the IL-6 level 5 days 
after illness onset was higher than levels 15 and 37 days 
after illness onset. The maximum IL-10 level 1 day after 
symptom onset was 3.2-fold higher than the baseline level. 
This level decreased to a value lower than the baseline level 
within 4 days, and then gradually increased to the baseline 
level 37 days after illness onset. Serum IL-6, IFN-γ, and 
IL-10 levels were not related to patient temperature 1 day 
after symptom onset, peak temperature during the disease, 
or period of fever. These levels showed minor differences 
that were not related to cough or sore throat in patients.
Only 1 patient had an HAI antibody titer ≥10 (titer 20) 
1 day after illness onset. The HAI geometric mean titer 
increased 5 days after symptom onset compared with that 
1 day after symptom onset and continued to increase until 
it reached a peak level of 137.9 at 37 days after symptom 
onset (25.5-fold increase). Peak HAI antibody titers ≥40 
and ≥4-fold increases were observed in 27 (96.4%) patients.
Conclusions
Bermejo-Martin et al. reported increased serum levels 
of IL-6, IFN-γ, and tumor necrosis factor-α in patients 
with pandemic (H1N1) 2009 during the ﬁ  rst 5 days after 
symptom onset; no difference in levels of these 3 cytokines 
was observed in patients with mild disease and controls 
(5). However, similar to another report (4), we detected 
increases of IL-6 and IFN-γ levels in patients with mild 
disease during the ﬁ  rst 3 days after symptom onset. These 
different patterns may be caused by different intervals from 
time of symptom onset to date of sample collection (5 days 
vs. 3 days) because IL-6 and IFN-γ levels in our study 
quickly decreased to baseline levels ≤7 days after symptom 
onset. These results suggest that serum IL-6 and IFN-γ 
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Figure 1. Flow cytometric analysis of peripheral blood lymphocyte 
subset counts of 28 patients with pandemic (H1N1) 2009, China. 
Counts and percentages are means. Error bars indicate SD. 
Each mean value was within the corresponding reference range. 
Lymphocyte subsets are as shown in the Table. A) Absolute count. 
B) Percentage of lymphocyte subset count compared with total 
lymphocyte count. *p<0.05; †p<0.01.
Figure 2. Serum cytoki    ne concentrations and hemagglutination 
inhibition (HAI) antibody titers of 28 patients with pandemic (H1N1) 
2009 during hospitalization and the follow-up period 15, 37, and 
49 days after symptom onset, China. Serum concentrations of 
interferon-γ (IFN-γ), interleukin-10 (IL-10), and IL-6 are medians 
(pg/mL). Serum HAI antibody titers were transformed by using 
the natural logarithm and are shown as means. Baseline cytokine 
concentrations on the y-axis are values for healthy persons. 
*p<0.05 when IL-6 or HAI antibody levels were compared with 
those at day 5; †p<0.05 when IL-10 level was compared with those 
at baseline; ‡p<0.05 when IL-10 level was compared with those at 
days 5 or 15; §p<0.05 when value was compared with that at any 
other time point; ¶p<0.05 when value was compared with those at 
days 5, 15, or 49.Immunologic Changes during Pandemic (H1N1) 2009
levels may be increased in patients with pandemic (H1N1) 
2009 within the ﬁ  rst 3 days after symptom onset, followed 
by a decrease to baseline levels ≤5 days after symptom 
onset in patients with mild disease or a continuous increase 
in severely affected patients.
IL-6 and IFN-γ are associated with antiviral immune 
responses during inﬂ   uenza infection (6–8). However, 
continuous, excessive release of IL-6 three days after 
illness onset likely contributed to serious pulmonary 
inﬂ  ammation and tissue injury, as has been documented 
for severe acute respiratory syndrome and 1918 pandemic 
inﬂ  uenza, but this release could be tempered by production 
of IL-10 (6,7,9–11).
The proportion of persons 18–60 years of age with 
a ≥4-fold increase in HAI titer who received 1 dose (15 
μg) of monovalent pandemic (H1N1) 2009 nonadjuvant 
vaccine was 96.2%, and the proportion with an increased 
HAI titer ≥40 was 97.1%, results similar to those of a 
recent study (12). However, the geometric mean titer in 
healthy vaccinated persons was 237.8, a 34.5-fold increase 
over the prevaccination titer, which was greater than that 
for patients naturally infected with pandemic (H1N1) 2009 
virus (12). This ﬁ  nding may have resulted from impaired 
adaptive immune responses against pandemic (H1N1) 
2009 virus in the initial phase, which included decreased 
numbers of CD4 and B lymphocytes and an increase in T 
regulatory cells (4).
In conclusion, our data indicated changes in cellular 
proﬁ   les during pandemic (H1N1) 2009 virus infection; 
showed that transient production of IL-6, IFN-γ, and IL-
10 are main effectors of the early innate immune response 
against pandemic (H1N1) 2009 virus; and indicated that 
adaptive immune responses are impaired in the initial 
phase after infection. These factors may help clarify the 
pathogenesis of pandemic (H1N1) 2009 virus and provide 
new approaches in overcoming severe infections.
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